Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT9283 in Relapsed or Refractory Multiple Myeloma
NCT01145989Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AT9283 in multiple myeloma (MM), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Response Rate at 3 years. Started Feb 2011; status: completed.
02
Drugs
AT9283
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01145989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145989.